ZURA Stock Forecast & Price Target

Zura Bio is viewed favorably because tibulizumab’s dual BAFF x IL-17A mechanism could address the efficacy ceiling seen in hidradenitis suppurativa, while also opening a second major opportunity in polymyalgia rheumatica and systemic sclerosis. The company’s catalysts are concentrated and near term, with TibuSHIELD enrollment exceeding target at 247 patients, a 4Q26 HS readout expected in late Oct./early Nov., a Phase II PMR start by year-end 2026, and SSc data in 1H27. Financially, Zura exited 2Q26 with $205.1 million in cash and a net loss of $26.3 million, giving runway through at least YE28 and supporting an attractive risk/reward profile.

Zura Bio is viewed negatively because its investment case is heavily dependent on tibulizumab, and any clinical or regulatory failure in its target indications would materially undermine the company’s lead asset and broader pipeline credibility. The company also faces a real risk that its programs may not demonstrate sufficient efficacy or could generate safety signals that halt development, which is especially problematic for a clinical-stage biotech with no proven commercial scale. Even if development succeeds, it may still struggle to achieve sales estimates due to competitive pressures from current and future therapies, while manufacturing and shipment issues add further execution risk.